TICKERNERD
Menu
BBOTBBOTHealthcare · Biotechnology

BBOT Stock Forecast: Bridgebio Oncology Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$2.80
+4.09% on the day

The 12 Wall Street analysts covering Bridgebio Oncology Therapeutics, Inc. hold a median 12-month price target of $22 — +685.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$215.7M
Ticker Nerd rank
6/ 100
Median analyst target
$22
Analysts covering
12
Revenue$0.0
Operating income−$60.2M
Net income−$56.5M
Free cash flow−$44.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.5%
1M
−26.5%
YTD
−77.6%
1Y
−75.1%
From 52W high
−79.6%
From 52W low
+6.1%
$3
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBOT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bridgebio Oncology Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
6/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
65
Volatility
49
Quality
42
Accruals
27
Revisions
26
Value
20
Issuance
13
Growth
8
Momentum
6

Size (65): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BBOT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBOT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26BBOTHigh $50Median $22Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $13Median $22High $50

The green dot is the last close — the median target sits +685.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 8 moved it down.

DateFirmActionRatingTarget
21 Oct 2026Morgan StanleyMaintainsOverweight$18 → $13
20 Oct 2026OppenheimerMaintainsOutperform$22 → $16
11 Sept 2026JP MorganMaintainsOverweight$25 → $23
11 Sept 2026JP MorganMaintainsOverweight—
10 Sept 2026Leerink PartnersMaintainsOutperform$39 → $27
10 Sept 2026Leerink PartnersMaintainsOutperform—
9 Sept 2026Canaccord GenuityMaintainsBuy—
9 Sept 2026Canaccord GenuityMaintainsBuy$23 → $20
9 Sept 2026Raymond JamesMaintainsOutperform$24 → $22
9 Sept 2026Raymond JamesMaintainsOutperform—
9 Sept 2026StifelMaintainsBuy$23 → $15
9 Sept 2026StifelMaintainsBuy—
9 Sept 2026WedbushReiteratesOutperform$25
9 Sept 2026WedbushReiteratesOutperform—
14 Aug 2026JP MorganMaintainsOverweight$27 → $25
14 Aug 2026JP MorganMaintainsOverweight—
8 July 2026JP MorganInitiatesOverweight$27
8 July 2026JP MorganInitiatesOverweight—
22 June 2026OppenheimerAssumesOutperform$22
11 May 2026Canaccord GenuityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BBOT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BBOT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Bridgebio Oncology Therapeutics, Inc. returned −75.1% against +13.6% for the S&P 500, dividends included.

BBOT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26BBOTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBOT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
9
Fundamentals

Bridgebio Oncology Therapeutics, Inc. (BBOT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.9%

Higher than 15% of US stocks

Return on assets
−47.1%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bridgebio Oncology Therapeutics, Inc. (BBOT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bridgebio Oncology Therapeutics, Inc. has a market value of $215.7M and an enterprise value of −$7.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$182.1M.

  • Diluted earnings per share, trailing twelve months: $−1,232.83.

  • Free cash flow in the twelve months to 30 June 2026: −$151.6M.

  • Shares outstanding: 80.1M.

  • Trailing P/E: −0.6×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Bridgebio Oncology Therapeutics, Inc. employs 88 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

BBOT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BBOTBridgebio Oncology Therapeutics, Inc.$215.7M6
ELDNEledon Pharmaceuticals, Inc.$224.3M34
IKTInhibikase Therapeutics, Inc.$226.0M36
SLGLSol-Gel Technologies Ltd.$222.9M52
EVMNEvommune, Inc.$227.3M11
KROSKeros Therapeutics, Inc.$228.9M72
CAMPCAMP4 Therapeutics Corp.$229.0M56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bridgebio Oncology Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBOT news & analysis

BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff

Seeking Alpha · 19 Oct 2026neutral

Seeking Alpha describes BBOT’s pipeline, led by BBO-11818, as targeting multiple KRAS mutations, while recent strategic shifts and clinical updates were followed by a 68% stock decline. The article cites a risk-adjusted valuation of $3.76 per share and 33% implied upside.

Why it matters — BBOT watchers may weigh the pipeline’s potential differentiation against concerns about commercial scope and execution that accompanied the selloff.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 12 Oct 2026neutral

BridgeBio Oncology Therapeutics announced an inducement grant awarded on October 10, 2026, under its 2025 Inducement Plan. The grant was made as a material inducement to the employment of one individual hired in September 2026.

Why it matters — The grant is a compensation-related corporate update for investors following BBOT’s hiring and equity awards.

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

GlobeNewsWire · 8 Sept 2026positive

BBOT announced new clinical data for its KRASG12C inhibitor BBO-8520 and outlined a strategic prioritization of BBO-8520 combined with a checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced NSCLC patients, as well as BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.

Why it matters — The announcement signals BBOT's focus on its RAS-pathway oncology pipeline and combination strategies, which are central to its near-term clinical development direction.

BBOT to Participate in Upcoming Investor Healthcare Conferences

GlobeNewsWire · 1 Sept 2026neutral

BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, announced that members of its leadership team will participate in upcoming investor healthcare conferences.

Why it matters — BBOT watchers may gain new insight into the company's progress and strategy as its leadership presents at these investor conferences.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 11 Aug 2026neutral

BridgeBio Oncology Therapeutics announced on August 11, 2026 that it awarded inducement grants on August 10, 2026 under its 2025 Inducement Plan, as a material inducement for the employment of two individuals hired by the company in July 2026. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — A BBOT watcher would care because the inducement grants signal the company is attracting and onboarding new talent as it advances its clinical-stage RAS-pathway oncology programs.

FAQ

Frequently asked questions about BBOT stock

What is the BBOT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Bridgebio Oncology Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $13 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBOT stock a buy right now?

Of the 12 analysts covering Bridgebio Oncology Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bridgebio Oncology Therapeutics, Inc. 6 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBOT?

As at 28 Oct 2026, Bridgebio Oncology Therapeutics, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (65 of 100).

Will BBOT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +685.7% from the last close, and Ticker Nerd's factor model ranks Bridgebio Oncology Therapeutics, Inc. 6 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBOT stock forecast for 2030?

No analyst covering Bridgebio Oncology Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $50 over the next 12 months.

How has BBOT stock performed over the past year?

Bridgebio Oncology Therapeutics, Inc. returned -75.1% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bridgebio Oncology Therapeutics, Inc. do?

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancers driven by RAS and PI3Kα pathway alterations.

What is the latest news on BBOT?

The most recent item we track (Seeking Alpha, 19 Oct 2026): "BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff". Seeking Alpha describes BBOT’s pipeline, led by BBO-11818, as targeting multiple KRAS mutations, while recent strategic shifts and clinical updates were followed by a 68% stock decline. The article cites a risk-adjusted valuation of $3.76 per share and 33% implied upside.

Company

About Bridgebio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancers driven by RAS and PI3Kα pathway alterations. BridgeBio Oncology Therapeutics designs oral, targeted oncology candidates intended to address some of the most common cancer-driving mutations, with a pipeline centered on RAS-related programs and precision cancer treatment. Its current work includes advancing investigational medicines that aim to inhibit KRAS and related signaling mechanisms, supporting the broader shift toward mutation-specific cancer care. Headquartered in South San Francisco, California, BridgeBio Oncology Therapeutics plays a specialized role in the oncology market by concentrating on difficult-to-target molecular pathways that are relevant across multiple solid tumors.

CEO Mr. Eli M. Wallace Ph.D. · 88 employees · United States · https://bbotx.com